Novo Nordisk presented the findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), at the American Diabetes Association’s 77th Scientific Sessions (ADA) in San Diego, US. Switching to Tresiba® provides significant reductions in blood glucose and lower rates of hypoglycaemia in a real-world setting
The study showed that people with type 1 diabetes and type 2 diabetes experienced a significant reduction in HbA1c (-0.2% for type 1 diabetes and -0.5% for type 2 diabetes) 6 months after switching to Tresiba® from another basal insulin, primarily insulin glargine U100 and insulin detemir, in a real-world setting. These results were sustained at 12 months.
Rates of overall hypoglycaemia were also significantly lower at 6 months after switching to Tresiba®. In people with type 1 diabetes, the rate of severe hypoglycaemia was reduced by 85% and by 92% in people with type 2 diabetes. Hypoglycaemia outcomes at 12 months were in line with these results.
“Real-world studies are important to understand how outcomes from clinical trials translate into real-world practice,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk. “Our real-world data presented at ADA reinforce what we have seen in the clinical trial programme, demonstrating improved glycaemic control and significantly reduced risk of hypoglycaemia when patients switched to Tresiba® from other basal insulins such as insulin glargine and insulin detemir.”